December 16, 2020
1 min watch
Save
Optimizing treatment for localized RCC, metastatic disease
Healio spoke with Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, on new developments in treatment for patients with renal cell carcinoma.
Specifically, researchers are assessing adjuvant therapies for patients with localized RCC and how to optimize therapy for previously treated patients with metastatic disease, she said.
Click here to watch the next video in the series on exciting areas of research in RCC.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Plimack reports serving as a scientific advisor for Bristol-Myers Squibb, Genentech, MEI, Merck and Seattle Genetics; conducting data safety monitoring for AstraZeneca, Pfizer and Infinity Pharma; receiving honorarium for CME presentations from ASCO GU, Clinical Care Options, Fox Chase Cancer Center, Mt. Sinai Icahn School of Medicine, NCCN, The Ohio State University, OncLive, PER, Research to Practice, Spire Learning and University of Hawaii; and receiving grants for clinical research from Astellas, Bristol-Myers Squibb, Genentech and Merck.